pasireotide LAR
Showing 1 - 25 of 188
Neuroendocrine Tumors, Carcinoid Tumors Trial in Stanford, Tampa (Pasireotide Long Acting Release (LAR))
Active, not recruiting
- Neuroendocrine Tumors
- Carcinoid Tumors
- Pasireotide Long Acting Release (LAR)
-
Stanford, California
- +1 more
Jan 11, 2022
Pituitary Tumor, ACTH-producing Pituitary Tumour Trial in New York (Pasireotide LAR)
Terminated
- Pituitary Tumor
- ACTH-producing Pituitary Tumour
- Pasireotide LAR
-
New York, New YorkNeuroendocrine Unit and Pituitary Center, Columbia University
Mar 31, 2021
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System Trial in Germany (Pasireotide LAR
Completed
- Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
- Pasireotide LAR followed by Pasireotide LAR + Everolimus
- Everolimus followed by Pasireotide LAR + Everolimus
-
Bad Berka, Germany
- +3 more
Dec 17, 2020
Metastatic Melanoma and Merkel Cell Carcinoma Trial in Essen, Lausanne, Zuerich (Pasireotide sub-cutaneous formulation,
Completed
- Metastatic Melanoma and Merkel Cell Carcinoma
- Pasireotide sub-cutaneous formulation
- Pasireotide lon acting release formulation
-
Essen, Germany
- +2 more
Dec 17, 2020
Neuroendocrine Carcinoma of the Lung and Thymus Trial in Worldwide (Pasireotide LAR, Everolimus, Pasireotide LAR and Everolimus
Completed
- Neuroendocrine Carcinoma of the Lung and Thymus
- Pasireotide LAR
- +2 more
-
Aarhus, Denmark
- +35 more
Mar 8, 2021
Neuroendocrine Tumors Trial in United States (Pasireotide LAR)
Completed
- Neuroendocrine Tumors
- Pasireotide LAR
-
Los Angeles, California
- +3 more
Dec 17, 2020
Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease Trial in Rochester (Pasireotide
Completed
- Somatostatin Analogs
- +3 more
- Pasireotide LAR
- Placebo
-
Rochester, MinnesotaMayo Clinic
Apr 30, 2020
Pancreatic Cancer Trial in Tampa (SOM 230 LAR, Gemcitabine)
Completed
- Pancreatic Cancer
- SOM 230 LAR
- Gemcitabine
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Sep 25, 2020
Cushing's Disease, Acromegaly, Neuroendocrine Tumors Trial in Worldwide (Pasireotide, Cabergoline)
Active, not recruiting
- Cushing's Disease
- +8 more
-
La Jolla, California
- +93 more
May 19, 2022
Acromegaly, Pituitary Gigantism Trial in Japan (Pasireotide LAR)
Completed
- Acromegaly
- Pituitary Gigantism
- Pasireotide LAR
-
Nagoya, Aichi, Japan
- +26 more
Aug 12, 2019
Non-functioning Pituitary Adenoma Trial in Brazil (Pasireotide LAR)
Completed
- Non-functioning Pituitary Adenoma
- Pasireotide LAR
-
Fortaleza, CE, Brazil
- +6 more
Apr 24, 2019
Cushing Disease Trial in France (Patient group, Remission control group, Bilateral surrenalectomy control group)
Recruiting
- Cushing Disease
- Patient group
- +2 more
-
Caen, France
- +6 more
Dec 16, 2021
Cushing's Disease, Acromegaly Trial in Worldwide (Pasireotide s.c., Sitagliptin, Liraglutide)
Completed
- Cushing's Disease
- Acromegaly
- Pasireotide s.c.
- +5 more
-
Multiple Locations, California
- +42 more
May 7, 2019
Somatostatin Receptors and GH Receptor Expression on Bone of
Completed
- Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients
- Trans-sphenoidal surgery
-
Roma, ItalyFondazione Policlinnico Gemelli IRCCS
Apr 6, 2023
Colorectal Cancer, Stoma Ileostomy Trial (Diverting loop ileostomy)
Not yet recruiting
- Colorectal Cancer
- Stoma Ileostomy
- Diverting loop ileostomy
- (no location specified)
Nov 21, 2023
Gastro-enteropancreatic Neuroendocrine Tumor Trial (Pasireotide, Diazoxide)
Withdrawn
- Gastro-enteropancreatic Neuroendocrine Tumor
- (no location specified)
Feb 17, 2022
Low Anterior Resection Syndrome in Newly Diagnosed Rectal
Recruiting
- Rectal Cancer
-
Taoyuan City, Kwei-Shan Dist., TaiwanChung Gung University
Jun 30, 2022
Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)
Not yet recruiting
- Triple-Negative Breast Cancer
- Trastuzumab Deruxtecan
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023